Evidence map›Paper›PMID 38125422›Full record

ArticleHeliyon2023

Genomic epidemiology reveals early transmission of SARS-CoV-2 and mutational dynamics in Nanning, China.

DeWu Bi, XiaoLu Luo, ZhenCheng Chen, ZhouHua Xie, Ning Zang, LiDa Mo, ZeDuan Liu, YanRong Lin, YaQin Qin, XiKe Tang and 9 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 2 institutions in 1 country.

DeWu BiDepartment of Clinical Laboratory, The Fourth People's Hospital of Nanning, Nanning, China.
XiaoLu LuoDepartment of Clinical Laboratory, The Fourth People's Hospital of Nanning, Nanning, China.
ZhenCheng ChenSchool of Life and Environmental Sciences, Guilin University of Electronic Technology, Guilin, China.
ZhouHua XieDepartment of Respiratory Medicine, The Fourth People's Hospital of Nanning, Nanning, China.
Ning ZangGuangxi Medical Research Center, Guangxi Medical University, Nanning, China.
LiDa MoDepartment of Clinical Laboratory, The Fourth People's Hospital of Nanning, Nanning, China.
ZeDuan LiuDepartment of Clinical Laboratory, The Fourth People's Hospital of Nanning, Nanning, China.
YanRong LinDepartment of Critical Care Medicine, The Fourth People's Hospital of Nanning, Nanning, China.
YaQin QinDepartment of Critical Care Medicine, The Fourth People's Hospital of Nanning, Nanning, China.
XiKe TangDepartment of Critical Care Medicine, The Fourth People's Hospital of Nanning, Nanning, China.
Lü LinEmergency Department, The Fourth People's Hospital of Nanning, Nanning, China.
YuanLi WangSchool of Life and Environmental Sciences, Guilin University of Electronic Technology, Guilin, China.
LiangLi CaoSchool of Life and Environmental Sciences, Guilin University of Electronic Technology, Guilin, China.
FeiJun ZhaoSchool of Life and Environmental Sciences, Guilin University of Electronic Technology, Guilin, China.
JinAi ZhouGuangxi Medical Research Center, Guangxi Medical University, Nanning, China.
ShanQiu WeiDepartment of Clinical Laboratory, The Fourth People's Hospital of Nanning, Nanning, China.
ShaoYong XiDepartment of Clinical Laboratory, The Fourth People's Hospital of Nanning, Nanning, China.
QiuYing MaDepartment of Clinical Laboratory, The Fourth People's Hospital of Nanning, Nanning, China.
JianYan LinKey Laboratory of Infectious Diseases, The Fourth People's Hospital of Nanning, Nanning, China.
Guangxi Medical University · CNGuilin University of Electronic Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants are a fatal pathogen resulting in substantial morbidity and mortality, and posing a great threat to human health with epidemics and pandemics.

methodsNext-generation sequencing (NGS) was performed to investigate the SARS-CoV-2 genomic characterization. Phylogenetic analysis of SARS-CoV-2 genomes was used to probe the evolutionary. Homology protein structure modelling was done to explore potential effect of the mutations.

resultsThe eighty genome sequences of SARS-CoV-2 obtained from the thirty-nine patients with COVID-19. A novel variant with mutation H625R concomitant with S50L in spike glycoprotein had been identified. Phylogenetic analysis revealed that SARS-CoV-2 variants belong to several distinct lineages. Homology modelling indicated that variant with mutation H625R and S50L increases flexibility of S1 subunit.

conclusionsSARS-CoV-2 genomes are constantly evolving by accumulation of point mutations. The amino acid H625R in combination with S50L may have a significant impact on the interaction between spike glycoprotein and ACE2.

Indexed as

COVID-19EvolutionMutationSARS-CoV-2Variant

Identifiers

PMID38125422
PMCPMC10731232
OpenAlexW4389152081

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.